Multiple blood diseases, including blood cell cancers (e.g.leukemia and myelodysplastic syndromes) and non-malignant blood cell disorders (e.g. immunodeficiencies, sickle cell anemia and thalassemia), critically require more effective therapies associated with fewer deleterious side effects. Members of the UW-Madison Blood Research Program have unique research programs dedicated to developing transformative therapeutic strategies involving new cellular targets, which are not targeted by existing drugs, and new synergistic drug combinations. This type of developmental work requires innovative, outside-the-box strategies and resource catalysts distinct from conventional research funding mechanisms, which often mandate conformance with existing paradigms.
Our goal is to open up entirely new therapeutic opportunities, rather than the common practice of incrementally modifying existing drugs and strategies. UW-Madison Blood Research Program faculty have trained at the most outstanding research institutions, have strong track records of making innovative and impactful discoveries at the UW-Madison, and are poised to make unique progress with direct clinical relevance – progress that would not be expected to emerge from ongoing research efforts nationally/internationally and from the private sector. If you have interest in the possibility of facilitating our mission to develop better diagnostic strategies and treatments for blood diseases and/or to train the next generation of researchers/scholars in this important field, please contact Dr. Bresnick to arrange a meeting to discuss the program, prioritized areas for catalysis, and your thoughts/goals. We very much appreciate your interest in our program and hope to have the opportunity to recruit you onto our team.
UW-Madison Blood Research Program
c/o Dr. Emery Bresnick
4009 WIMR, L4
1111 Highland Ave
Madison, WI 53705